Join Dana Rizk, MD (University of Alabama at Birmingham, USA), and Shikha Wadhwani, MD (Indiana University School of Medicine, USA), for a conversation on the treatment revolution in IgAN. They discuss how breakthroughs in understanding disease pathophysiology are fueling a wave of new therapies that go beyond traditional supportive care.

Key topics include what's changed since the KDIGO 2021 Guideline, the four-hit hypothesis and its role in driving novel therapies, key factors to consider when selecting treatments, and the evolving role of traditional approaches alongside newer agents.

This podcast was supported by Travere.

Join Dana Rizk, MD (University of Alabama at Birmingham, United States), and Brad Rovin, MD (Ohio State University, United States), Co-Chair of the 2025 KDIGO IgAN/IgAV Guideline, for a deep dive into the latest updates in patient care. Their conversation explores the most important takeaways from the new guideline, the critical role of kidney biopsies in diagnosis and prognosis, the use of the IgAN prediction tool for risk assessment, and the updated thresholds and treatment goals designed to improve outcomes.

This podcast was supported by Travere.

What does life with a rare kidney disease really look like?

Marianne Silkjaer Nielsen (Founder of CompCure, Denmark) offers a powerful voice for patients and caregivers. She reflects on the long diagnostic journey, the challenges of managing rare kidney disease, and the need for better awareness, advocacy, and international registries to improve outcomes.

This episode is part of a four-part KDIGO Conversations in Nephrology series on complement-mediated kidney diseases, hosted by Dr. Carla Nester (University of Iowa Stead Family Children’s Hospital, United States).

This series was supported by Apellis and Sobi.

What does the future of treatment for C3 Glomerulopathy (C3G) look like?

Dr. Nicole van de Kar (Radboud University Medical Center, The Netherlands) unpacks the pathophysiology of C3G, from genetic and autoantibody factors to the central role of the alternative pathway. She explores the limits of current C5 therapies and the potential of new strategies targeting C3 activation that could reshape patient care worldwide.

This episode is part of a four-part KDIGO Conversations in Nephrology series on complement-mediated kidney diseases, hosted by Dr. Carla Nester (University of Iowa Stead Family Children’s Hospital, United States).

This series was supported by Apellis and Sobi.

How do patients with C3 Glomerulopathy (C3G) present, and why is confirming the diagnosis so complex?

Dr. David Kavanagh (National Renal Complement Therapeutics Centre, United Kingdom) walks through the diagnostic process, the shortcomings of traditional immunosuppression, and the promise of emerging therapies like alternative pathway inhibitors. He also tackles one of the toughest challenges: managing post-transplant recurrence.

This episode is part of a four-part KDIGO Conversations in Nephrology series on complement-mediated kidney diseases, hosted by Dr. Carla Nester (University of Iowa Stead Family Children’s Hospital, United States).

This series was supported by Apellis and Sobi.

Why does it matter if a kidney disease is complement-driven or complement-associated?

Dr. Matthew Pickering (Imperial College London, United Kingdom) explains this critical distinction and why it changes how clinicians approach diagnosis and treatment. The discussion explores promising new therapies such as C3 and C5 inhibitors and how biomarkers are paving the way for precision medicine in nephrology.

This episode is part of a four-part KDIGO Conversations in Nephrology series on complement-mediated kidney diseases, hosted by Dr. Carla Nester (University of Iowa Stead Family Children’s Hospital, United States).

This series was supported by Apellis and Sobi.

Episode 19 is the third episode in KDIGO's three-episode series on acute kidney injury (AKI), hosted by Dr. Kathleen Liu (University of California at San Francisco, United States).

In this episode, Dr. Liu and Dr. Claudio Ronco (International Renal Research Institute of San Bortolo Hospital, Italy) discuss recent advancements and best practices surrounding Extracorporeal Blood Purification within the complex scenario of multiorgan support. This thought-provoking discussion, explores:

Join Dr. Liu and Dr. Ronco for an insightful exploration of extracorporeal blood purification’s evolving role in optimizing care for critically ill patients. 

This episode is supported by an independent educational grant from Baxter.

Episode 18 is the second episode in KDIGO's three-episode series on acute kidney injury (AKI), hosted by Dr. Kathleen Liu (University of California at San Francisco, United States). In this episode, Dr. Liu is joined by Dr. Kianoush Kashani (Mayo Clinic, United States) to discuss the rising importance of personalized care in AKI treatment. They delve into the world of digital health, exploring how digital decision support tools can empower clinicians and improve patient outcomes.

This episode will address:

Tune in for this informative discussion on leveraging the power of digital health to personalize AKI care.

This episode is supported by an independent educational grant from Baxter.

This is the first episode in KDIGO's new 3-episode series on acute kidney injury (AKI), hosted by Dr. Kathleen Liu (University of California at San Francisco, United States).
In this episode, Dr. Liu is joined by Dr. Jay Koyner (University of Chicago, United States) to discuss the emerging field of persistent acute kidney injury (AKI).

They delve into the question: what exactly is persistent AKI, and how does it differ from severe AKI? Dr. Liu and Dr. Koyner explore the key factors clinicians should consider when evaluating a patient's risk of developing persistent AKI. They also highlight the latest developments in this area of nephrology research, leaving listeners with valuable insights into the diagnosis and management of persistent AKI.

Join us as we discuss:

This episode is supported by an independent educational grant from Baxter.